Skip to content
x.com· @ · X·· 2026-04-22Score60

daraxonrasib

Reading

KRAS / RAS targeting: from platform to Phase 3

The floor also showed dual ON/OFF (VS-7375) and RM-055, built for amplification and daraxonrasib-resistant models.

The floor rewrote the question from “how long can G12C monotherapy last” to “who first makes first-line pancreatic cancer a standard.” daraxonrasib’s Phase 3 is still the only RAS-inhibitor overall-survival win.

Body

$RVMD Cowen RVMD (Buy) - Revved Up for PDAC Domination #AACR26 RVMD presented further support for daraxonrasib's 1L use as both mono and in chemo combo. The 6mo PFS rates for mono/combo of 71/84% and 6mo OS of 83/90% track well above SoC chemo and we expect the gap to continue widening with more maturity given the RASolute302 OS outcome. updated model to include darax peak U.S. PDAC sales of $9B

Heat 11 · 8 likes · 0 replies · 3 reposts

Conference abstracts
LB407NCT05379985NCT06445062matched by 药名 daraxonrasib
Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC)

Brian M. Wolpin, Benjamin L. Musher, Gulam A. Manji, Wungki Park, Alexander Spira, Nilofer Azad, Vaia Florou, Tiago Biachi De Castria, Mark H. O'Hara, Erkut Borazanci, Aparna Parikh, John Strickler, Joel Randolph Hecht, Shubham Pant, Shiraj Sen, E. Gabriela Chiorean, W. Clay Gustafson, Hina Patel, Vidya Seshadri, Yan Zheng, Davendra Sohal

Read the abstract →

Source: x.com · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org